Date	Title	Document
Date 12/22/22	Title First tazarotene lotion treatment for acne vulgaris, ARAZLO™ (tazarotene lotion, 0.045%), now available to patients through Quebec, Ontario, Alberta, Saskatchewan and federal NIHB public drug plans	Document PDF
Date 12/02/22	Title Bausch Health Wins DUOBRII® and BRYHALI® Patent Infringement Case	Document PDF
Date 12/01/22	Title Salix Pharmaceuticals Culminates Year-Long Constipation Awareness Campaign with New Social Media and Digital Initiatives Empowering Patients to Discuss Their Symptoms with a Health Care Provider	Document PDF
Date 11/29/22	Title Bausch Health Announces the Unrestricting of Bausch + Lomb Under Bausch Health Debt Covenants	Document PDF
Date 11/04/22	Title Salix Will Present Rifaximin Data at AASLD's The Liver Meeting(R) 2022	Document PDF
Date 11/03/22	Title Bausch Health Companies Inc. Announces Third-Quarter 2022 Results	Document pdf
Date 11/01/22	Title Ortho Dermatologics to Present New Data at the 2022 Innovations in Dermatology Conference	Document PDF
Date 10/31/22	Title Ortho Dermatologics Announces U.S. Launch of the Podiatry Board Review Challenge	Document PDF
Date 10/24/22	Title Salix Will Present XIFAXAN(R) (Rifaximin), TRULANCE(R) (Plecanatide) and RELISTOR(R) (Methylnaltrexone Bromide) Data at The American College of Gastroenterology(R) 2022 Annual Scientific Meeting	Document PDF
Date 10/20/22	Title Ortho Dermatologics To Present New Data at the 2022 Fall Clinical Dermatology Conference	Document PDF
Date 10/13/22	Title Bausch Health to Announce Third Quarter 2022 Results on Nov. 3	Document pdf
Date 10/12/22	Title Salix Pharmaceuticals Releases Liver Health Annual Trends Report Underscoring Challenges in Caring for Growing Chronic Liver Disease and Cirrhotic Patient Population	Document PDF
Date 10/05/22	Title Seasonal Affective Disorder (SAD) Is Now a Recognized Diagnosis in the CMS Tabular Index, Accessible to Prescribers Oct. 1, 2022	Document pdf
Date 10/03/22	Title Salix Pharmaceuticals Applauds Implementation of K76.82 – a New ICD-10 Code for Hepatic Encephalopathy	Document pdf
Date 09/28/22	Title Bausch Health Announces Final Results and Expiration of Exchange Offers and Consent Solicitations	Document pdf
Date 09/14/22	Title Bausch Health Announces Early Exchange Offer Results for Exchange Offers and Consent Solicitations	Document pdf
Date 09/09/22	Title Bausch Health Responds to Norwich Pharmaceuticals Tentative FDA Approval for a 200 mg Rifaximin	Document pdf
Date 09/08/22	Title Bausch Health Clarifies Release Provisions Related to its Exchange Offers and Consent Solicitations	Document pdf
Date 08/30/22	Title Bausch Health Announces Exchange Offers and Consent Solicitations for Certain Existing Senior Notes with Support from Approximately 23% of Outstanding Existing Senior Notes	Document pdf
Date 08/22/22	Title Bausch Health Continuing Process Toward Separating Bausch + Lomb	Document pdf
Date 08/10/22	Title Bausch Health to Appeal XIFAXAN® Patent Decision to U.S. Court of Appeals for the Federal Circuit	Document PDF
Date 08/10/22	Title Salix Supports CMS Announcement of First ICD-10 Code for Hepatic Encephalopathy (HE)	Document PDF
Date 08/09/22	Title Bausch Health Announces Second-Quarter 2022 Results	Document pdf
Date 07/28/22	Title Bausch Health Provides Update Following Oral Order in XIFAXAN® Patent Litigation	Document PDF
Date 07/27/22	Title Bausch Health Companies Inc. Will Release Second-Quarter 2022 Financial Results on Aug. 9	Document PDF
Date 07/13/22	Title Salix Announces 2022 Gastrointestinal Health Scholars Program Winners	Document PDF
Date 06/23/22	Title Bausch Health Announces 2022 Annual Meeting of Shareholder Results, Updates to its Board of Directors	Document PDF
Date 06/21/22	Title Bausch Health Issues Form 8-K for 2022 Annual Meeting of Shareholders Presentation	Document PDF
Date 06/20/22	Title Salix to Share New Data from XIFAXAN® (Rifaximin) Clinical Research at EASL's International Liver Congress™ 2022	Document PDF
Date 06/16/22	Title Bausch Health Provides Update on Solta Medical	Document PDF
Date 05/18/22	Title Salix Pharmaceuticals To Share New Data At Digestive Disease Week® 2022	Document PDF
Date 05/11/22	Title Bausch Health Announces Participation In Upcoming Investor Conferences	Document PDF
Date 05/10/22	Title Bausch Health And Bausch + Lomb Corporation Announce Closing Of Initial Public Offering Of Bausch + Lomb And Related Debt Transactions	Document PDF
Date 05/10/22	Title Bausch Health Companies Inc. Announces First-Quarter 2022 Results	Document pdf
Date 05/06/22	Title Bausch Health Announces Thomas J. Appio As Chief Executive Officer	Document PDF
Date 05/05/22	Title Bausch + Lomb Corporation Announces Pricing of IPO	Document pdf
Date 05/03/22	Title Bausch + Lomb Presents Data from Second Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the Association for Research in Vision and Ophthalmology Annual Meeting	Document PDF
Date 04/29/22	Title Bausch Health Companies Inc. Will Release First-Quarter 2022 Financial Results On May 10	Document PDF
Date 04/28/22	Title Bausch + Lomb Corporation Announces Launch of IPO and Roadshow	Document pdf
Date 04/28/22	Title Bausch Health Enters Into Arrangement Agreement with Bausch + Lomb Corporation in Connection with Previously Announced Proposed Separation	Document pdf
Date 04/28/22	Title Bausch + Lomb Will Present New Scientific Data and Analyses on Products and Pipeline Programs During the Association for Research in Vision and Ophthalmology Meeting	Document PDF
Date 04/27/22	Title Ortho Dermatologics Will Present Data at the 2022 Florida Society of Dermatology Physician Assistants New Wave Dermatology Conference	Document PDF
Date 04/25/22	Title Bausch + Lomb Presents Data from First Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the American Society of Cataract and Refractive Surgery Annual Meeting	Document pdf
Date 04/21/22	Title Bausch + Lomb Reports More Than 48 Million Units of Contact Lens, Eye Care and Lens Care Materials Recycled Through ONE by ONE and Biotrue® Eye Care Recycling Programs	Document pdf
Date 04/20/22	Title Bausch + Lomb Corporation Seeking to Enter Into New Credit Facilities to Facilitate Previously Announced Separation from Bausch Health	Document PDF
Date 04/18/22	Title Bausch + Lomb Will Present New Scientific Data During the American Society of Cataract and Refractive Surgery Annual Meeting	Document pdf
Date 04/04/22	Title HALF OF IBS PATIENTS SURVEYED REPORT IBS SYMPTOMS MORE CHALLENGING TO MANAGE IN THE PAST YEAR	Document PDF
Date 03/29/22	Title Bausch Health Will Reduce Debt By $200 Million	Document pdf
Date 03/28/22	Title Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis	Document pdf
Date 03/24/22	Title New Data on Cost Impact of Treating Opioid-Induced Constipation (OIC) with FDA-Approved Medications, Including Salix's RELISTOR® Subcutaneous Injection (Methylnaltrexone Bromide), in The Emergency Department Is Published in Advances In Therapy	Document PDF
Date 03/22/22	Title Gary Gemignani Will Join Solta Medical Corporation As Chief Financial Officer	Document PDF
Date 03/22/22	Title Ortho Dermatologics Will Present New Data at the 2022 American Academy of Dermatology Annual Meeting	Document PDF
Date 03/03/22	Title Bausch Health Announces Participation in Upcoming Investor Conferences	Document PDF
Date 03/02/22	Title Ortho Dermatologics Now Accepting Applications for 2022 Aspire Higher Scholarship Program	Document PDF
Date 03/01/22	Title Salix and Colon Cancer Coalition Join Forces for 'Faces of Blue' Story Series to Raise Awareness of Colorectal Cancer Screenings	Document PDF
Date 02/24/22	Title Bausch Health Announces Participation At The J.P. Morgan Global High Yield & Leveraged Finance Conference	Document PDF
Date 02/23/22	Title Bausch Health Companies Inc. Announces Fourth-Quarter And Full-Year 2021 Results And Provides 2022 Guidance	Document pdf
Date 02/22/22	Title OraPharma Launches OraFit™ Custom Clear Dental Aligner System	Document PDF
Date 02/15/22	Title Salix Announces 2022 Gastrointestinal Health Scholars Program	Document PDF
Date 02/08/22	Title Solta Medical Corporation Files Registration Statement for Proposed Initial Public Offering	Document PDF
Date 02/03/22	Title Bausch Health Companies Inc. Will Release Fourth-Quarter and Full-Year 2021 Financial Results on February 23	Document PDF
Date 02/01/22	Title BAUSCH + LOMB AND PREVENT BLINDNESS LAUNCH ANNUAL AMD AWARENESS MONTH CAMPAIGN TO EDUCATE PATIENTS	Document PDF
Date 01/27/22	Title Bausch Health Announces Pricing Of Private Offering Of Senior Secured Notes	Document PDF
Date 01/27/22	Title Bausch Health Announces Launch Of Private Offering Of Senior Secured Notes	Document PDF
Date 01/20/22	Title Dr. Yehia Hashad Will Join Bausch + Lomb Corporation as Executive Vice President of Research & Development and Chief Medical Officer	Document PDF
Date 01/18/22	Title Bausch Health Announces It Is Seeking To Refinance Its Existing Credit Agreement And Conditional Redemption Of Existing Notes - These Steps Will Enable Bausch + Lomb IPO And Facilitate Full Separation	Document PDF
Date 01/13/22	Title Bausch + Lomb Corporation Files Registration Statement and Preliminary Prospectus for Proposed Initial Public Offering	Document PDF
Date 01/11/22	Title Bausch Health Will Provide Business And Strategic Update At The 40th Annual J.P. Morgan Healthcare Conference	Document PDF
Date 01/05/22	Title Bausch Health to Participate at the 40th Annual J.P. Morgan Healthcare Conference	Document PDF
Date 01/04/22	Title New Survey from Bausch + Lomb and Glaucoma Research Foundation Reveals Emotional and Social Impact of Hyperemia on Glaucoma Patients	Document pdf